Date of Last Revision

2023-05-02 18:57:51


Chemical Engineering - Cooperative Education

Degree Name

Bachelor of Science

Date of Expected Graduation

Spring 2016


Protein modification shows promise for improving the effectiveness of protein therapy, including the use of Interferon-beta-1b for the treatment of multiple sclerosis. The addition of a chain of 50 lysine and glutamic acid residues (also called a KE50 modification) was tested on green fluorescent protein (AcGFP) to determine its effect on the bioactivity of the protein. Standard transformation protocol was used to grow the normal and modified proteins in E.Coli, and the bioactivity of the protein was measured using quantum yield and extinction coefficients to determine the reduction in brightness from the native form to the modified form. The brightness of the modified protein was reduced to 65% of the original brightness, showing that the modification reduces protein bioactivity but does not eliminate it. The same transformation experiment was attempted to grow native and KE50 modified versions of interferon-beta-1b, but the growth of the protein in E.Coli was not successful. If future efforts to create a modified version of interferon-beta-1b are successful, it could prove to be a more successful treatment for multiple sclerosis which has reduced immunogenicity and longer residence time in the blood compared to the current treatment.

Research Sponsor

Gang Cheng

First Reader

Lingyun Liu

Second Reader

Bi-min Zhang Newby



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.